IL-17F Capture Agents With Cooperative Ligand Binding for Sensitive Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting IL-17A and IL-17F biomarkers are limited by their low natural abundance and require highly sensitive detection techniques, while existing approaches to block IL-17A interaction are not effective for IL-17F, necessitating improved capture agents for IL-17F detection.
Innovation Solution
Development of chemically synthesized capture agents, known as protein-catalyzed capture agents (PCC Agents), designed to bind specifically to IL-17F with enhanced affinity, utilizing anchor ligands and linkers to form stable complexes, enabling sensitive detection through immunoassays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional sandwich immunoassays are used to detect IL-17A and IL-17F, then the detection method is simple and established, but the detection sensitivity is insufficient due to low natural abundance of these cytokines
Solution Approach 1:
The patent changes the chemical parameters of the capture agents by using non-natural amino acids with unique reactive groups (azides and alkynes) that enable selective chemical ligation. This allows the formation of capture agents with optimized binding properties and enhanced detection sensitivity for low-abundance IL-17 cytokines, resolving the contradiction between detection sensitivity and assay complexity.
Solution Approach 2:
The patent creates composite capture agents by chemically ligating multiple peptide components containing non-natural amino acids. These composite structures combine multiple binding functionalities in a single agent, significantly enhancing detection sensitivity for IL-17A and IL-17F while maintaining manageable assay complexity through standardized chemical coupling protocols.
2Reliability
If monoclonal antibodies are used to block IL-17A interaction with its receptor, then the therapeutic approach is effective for IL-17A, but it does not provide effective treatment for IL-17F
Solution Approach 1:
The patent designs capture agents with the universal capability to detect multiple IL-17 cytokines (IL-17A, IL-17F, and heterodimers) using the same chemical platform. By incorporating non-natural amino acids that can be selectively ligated to target different epitopes, the system achieves multi-cytokine coverage while maintaining reliable detection effectiveness for each specific cytokine.
Solution Approach 2:
The patent applies local quality by designing specific peptide sequences with non-natural amino acids at strategic positions to target distinct epitopic regions on different IL-17 cytokines. This allows the same chemical platform to generate specialized capture agents for each cytokine variant, achieving both specificity and versatility in treatment approaches.
3Measurement precision
If chemically synthesized capture agents with non-natural amino acids are used to detect IL-17F, then the detection sensitivity and specificity are enhanced, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies preliminary action by first incorporating non-natural amino acids (with azide or alkyne groups) into peptide sequences during standard solid-phase peptide synthesis, before the final ligation step. This preliminary incorporation simplifies the overall manufacturing process by using well-established peptide synthesis technology for the initial stages, reserving the more complex chemical ligation for the final assembly step only.
Solution Approach 2:
The patent uses non-natural amino acids with reactive groups (azides and alkynes) as intermediary components that facilitate modular assembly of capture agents. These intermediary groups enable selective chemical ligation between peptide fragments under mild conditions, simplifying the manufacturing process by allowing stepwise assembly rather than requiring synthesis of complete complex structures in one step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PCC Agents provide stable and selective detection of IL-17F, offering greater affinity than IL-17A, and are suitable for use in various biological samples, enhancing diagnostic capabilities.
Implementation Method 1
a stable, synthetic capture agent that specifically binds IL-17F, wherein the capture agent comprises one or more designed anchor ligands
Implementation Method 2
the first ligand and the second ligand cooperatively bind the first and second epitopes of IL-17F, respectively
Implementation Method 3
a linker covalently connecting the first ligand to the second ligand
Data Source
AI summary
The present application provides stable peptide-based IL-17F capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.